Clinical Trials | December 08, 2025
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
HYMPAVZI’s safety profile was generally favorable
HYMPAVZI’s safety profile was generally favorable
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Subscribe To Our Newsletter & Stay Updated
